Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 8.49 CHF 5.47% Market Closed
Market Cap: 165.2m CHF
Have any thoughts about
Newron Pharmaceuticals SpA?
Write Note

Newron Pharmaceuticals SpA
Investor Relations

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 25 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

Show more

Earnings Calls

No Earnings Calls Available

Management

Mr. Stefan Weber
CEO & Executive Director
No Bio Available
Mr. Roberto Galli
Chief Financial Officer
No Bio Available
Mr. Filippo Moriggia
Vice President of Operations
No Bio Available
Dr. Ravi Anand M.D., Ph.D.
Chief Medical Officer
No Bio Available
Ms. Laura Faravelli
Vice President of Business Development
No Bio Available

Contacts

Address
MILANO
Bresso
Via Ludovico Ariosto 21
Contacts
+39026103461.0
www.newron.com